TABLE 1.
Patient characteristics (n = 421)
| Age a (years) | 74.0 (68.0–79.0) |
|---|---|
| Sex (female/male) | 81/340 |
| ECOG‐PS (0/1/≥2) | 336/71/14 |
| Body mass index (kg/m2) | 22.9 (20.8–25.6) |
| Etiology of HCC (hepatitis B/C/B + C/non‐B, non‐C) | 68/144/1/208 |
| Albumin (g/dl) a | 3.7 (3.3–4.1) |
| Total bilirubin (mg/dl) a | 0.8 (0.6–1.0) |
| CRP (mg/dl) a | 0.30 (0.10–0.79) |
| Platelet count (×103/m3) a | 13.9 (10.6–18.9) |
| Neutrophils (×103/m3) a | 2920 (2158–3927) |
| Lymphocytes (×103/m3) a | 1130 (790–1521) |
| Prothrombin time (%) a | 90 (82–100) |
| α‐fetoprotein level (ng/ml) a | 42.5 (6.7–581.0) |
| Child–Pugh score (5/6/≥7) | 246/144/31 |
| ALBI grade (1/2/3) | 148/269/4 |
| BCLC stage (≤A/B/≥C) | 21/154/246 |
| NLR a | 2.58 (1.84–3.66) |
| GPS (0/1/2) | 239/130/52 |
| Neo‐GPS (0/1/2) | 132/212/77 |
| Atez/Bev therapy type (first line/other) | 259/162 |
| Follow‐up duration a (months) | 8.7 (5.0–13.2) |
Abbreviations: ALBI, albumin–bilirubin; Atez/Bev, atezolizumab plus bevacizumab; BCLC, Barcelona Clinic Liver Cancer; CRP, C‐reactive protein; ECOG‐PS, Eastern Cooperative Oncology Group Performance Status; GPS, Glasgow prognostic score; HCC, hepatocellular carcinoma; NLR, neutrophil‐to‐lymphocyte ratio.
a
Data expressed as medians (interquartile range).